10-K: PetVivo Holdings Reports FY26 Results, Focus on Spryng Commercialization

PetVivo Holdings, Inc. filed its annual report for the fiscal year ended March 31, 2026, detailing revenues of $1.14 million and a net loss of $10.47 million, while highlighting progress in product development and distribution partnerships.

Summary

• PetVivo Holdings, Inc. reported revenues of $1,141,607 for the fiscal year ended March 31, 2026, a slight increase from $1,132,533 in the prior year.
• The company incurred a net loss of $10,473,672 for fiscal year 2026, compared to a net loss of $8,399,166 in fiscal year 2025.
• Operating expenses increased to $9,817,713 in fiscal year 2026, primarily due to higher sales and marketing expenses related to the commercialization of its PrecisePRP product.
• The company's cash and cash equivalents stood at $200,782 as of March 31, 2026, with management anticipating the need for additional capital to sustain operations.
• PetVivo has a pipeline of 17 products for animal and human treatment, protected by a portfolio of patents and trade secrets.
• The company's lead product, Spryng, is an intra-articular injection for osteoarthritis in dogs and horses.
• Distribution partnerships were established with Vedco Inc. and Clipper Distributing, LLC in December 2024.
• The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient working capital.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss, rising operating expenses, and the auditor's going concern warning, despite some positive developments in product pipeline and new distribution partnerships.

Positives

• Revenues saw a slight increase to $1,141,607 in fiscal year 2026.
• The company has a diverse product pipeline with 17 potential products for animal and human applications.
• New wholesale distribution partnerships were established with Vedco Inc. and Clipper Distributing, LLC in December 2024.
• The company is actively pursuing advancements in its proprietary biomaterials and manufacturing processes.
• The company has a portfolio of 19 patents protecting its technology.

Negatives

• The company reported a net loss of $10,473,672 for fiscal year 2026.
• Operating expenses increased significantly, driven by higher sales and marketing costs.
• Cash and cash equivalents were low at $200,782 as of March 31, 2026, indicating a need for further financing.
• The company's independent auditors have raised substantial doubt about its ability to continue as a going concern.
• The company terminated its distribution agreements with MWI and Covetrus North America in March 2025 and February 2025, respectively.
• An impairment expense of $1,000,000 was recorded related to the VetStem licensing agreement due to lower-than-expected sales of the PrecisePRP product.

Risks

• The company has a limited operating history and has incurred substantial losses, with no assurance of future profitability.
• Failure to obtain sufficient funding could lead to material reductions or discontinuation of business operations.
• Dependence on the success of Spryng and its market acceptance by veterinarians and pet owners.
• Intense competition from major pharmaceutical, biotechnology, and specialty animal health companies.
• Reliance on third parties for clinical studies, with limited control over their timelines and resources.
• Potential inability to manage rapid growth effectively, leading to strain on resources.
• Risks associated with manufacturing and supply chain management, including timely procurement of raw materials.
• Potential for intellectual property infringement claims and the cost of enforcing or defending IP rights.
• The market price of common stock is highly volatile and may be subject to significant fluctuations.
• The company's internal controls over financial reporting were not effective as of March 31, 2026.
• The company does not anticipate paying any dividends for the foreseeable future.

Future Outlook

The company anticipates needing to raise additional capital to fund its operations and business expansion, including the commercialization of Spryng and other products. The ability to secure future financing is subject to business performance and market conditions.

Management Comments

• The independent auditors report accompanying our March 31, 2026, financial statements contain an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern.
• We expect to continue to raise additional capital through the sale of our securities from time to time for the foreseeable future to fund our business expansion.
• Our ability to obtain such additional capital will likely be subject to various factors, including our overall business performance and market conditions.
• We believe that having two manufacturing facilities will help us minimize supply risks, allow for continued scaling or our production capacity, and expand our research and development facilities.

Industry Context

StockSavvy.ai notes that PetVivo Holdings operates in the competitive animal health market, which is experiencing growth driven by increased pet ownership. The company's focus on osteoarthritis treatments for dogs and horses places it in a significant segment of this market, though competition from established players remains a key factor.

Legal Proceedings

• A former employee filed a whistleblower retaliation complaint with OSHA under Sarbanes-Oxley Act (SOX), alleging wrongful termination after reporting governance and honesty issues. The company denies allegations and is cooperating with the investigation.

Stakeholder Impact

• Shareholders may experience continued stock price volatility and potential dilution if additional capital is raised through equity offerings.
• Veterinarians and pet owners are the primary customers for Spryng, and their adoption rate is critical to the company's success.
• Distributors play a key role in product sales, and the company's ability to maintain and develop these relationships is important.

Next Steps

• Continue commercialization efforts for Spryng in the United States.
• Pursue additional third-party studies related to Spryng for osteoarthritis treatment in canine and equine patients.
• Advance and improve manufacturing systems for Spryng to increase product volume and efficiency.
• Conduct research and testing on existing Spryng formulations and variations to identify next commercial products for navicular disease in horses.
• Explore acquisition or in-licensing of additional proprietary products for pets.
• Establish strategic out-licensing partnerships for secondary revenues.

Key Dates

Recommendation

While PetVivo Holdings shows promise with its product pipeline and patented technology in the growing animal health market, the significant net loss, ongoing operational expenses, and the auditor's going concern warning necessitate a cautious approach. The company's ability to secure future financing and successfully commercialize its products, particularly Spryng, remains critical. Investors should monitor progress on sales, distribution, and financial stability before considering a more aggressive stance.

Keywords

PetVivo Holdings, Form 10-K, Annual Report, Spryng, Osteoarthritis, Veterinary Medical Device, Animal Health, Biomaterials, OTC Markets, SEC Filing